Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases. More Details
Flawless balance sheet with weak fundamentals.
Share Price & News
How has Galectin Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: GALT has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: GALT underperformed the US Biotechs industry which returned 31.2% over the past year.
Return vs Market: GALT underperformed the US Market which returned 12.8% over the past year.
Price Volatility Vs. Market
How volatile is Galectin Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StCould The Galectin Therapeutics, Inc. (NASDAQ:GALT) Ownership Structure Tell Us Something Useful?
2 months ago | Simply Wall StHow Many Galectin Therapeutics, Inc. (NASDAQ:GALT) Shares Have Insiders Sold, In The Last Year?
3 months ago | Simply Wall StGalectin Therapeutics (NASDAQ:GALT) Is In A Good Position To Deliver On Growth Plans
Is Galectin Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate GALT's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate GALT's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: GALT is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: GALT is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate GALT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: GALT is overvalued based on its PB Ratio (4.7x) compared to the US Biotechs industry average (3.6x).
How is Galectin Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GALT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: GALT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: GALT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if GALT's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if GALT's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if GALT's Return on Equity is forecast to be high in 3 years time
How has Galectin Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GALT is currently unprofitable.
Growing Profit Margin: GALT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: GALT is unprofitable, but has reduced losses over the past 5 years at a rate of 5.3% per year.
Accelerating Growth: Unable to compare GALT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GALT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).
Return on Equity
High ROE: GALT has a negative Return on Equity (-47.53%), as it is currently unprofitable.
How is Galectin Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: GALT's short term assets ($41.1M) exceed its short term liabilities ($4.3M).
Long Term Liabilities: GALT's short term assets ($41.1M) exceed its long term liabilities ($31.0K).
Debt to Equity History and Analysis
Debt Level: GALT is debt free.
Reducing Debt: GALT has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GALT has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: GALT has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 3.6% each year.
What is Galectin Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GALT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GALT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GALT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GALT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of GALT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Joel Lewis (50 yo)
Mr. Joel Lewis serves as Chief Executive Officer and President at Galectin Therapeutics, Inc since August 31, 2020 and Director since December 14, 2017. He served as the Managing Director of Shareholder Se ...
|CFO, Treasurer & Secretary||7.17yrs||US$778.12k||0.0074% |
|Consultant & Director||0.75yr||US$1.31m||0.015% |
|General Counsel||no data||no data||no data|
|Executive Vice President of Manufacturing & Product Development||20.67yrs||US$134.47k||no data|
|Chief Medical Officer||0.50yr||no data||no data|
Experienced Management: GALT's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.
|Consultant & Director||0.75yr||US$1.31m||0.015% |
|Independent Director||11.58yrs||US$181.10k||0.22% |
|Independent Director||6yrs||US$179.10k||0.14% |
|Independent Chairman||2.33yrs||US$188.26k||13.84% |
|Independent Director||8.92yrs||US$134.28k||0.024% |
|Co-founder & Member of the Scientific Board||no data||US$203.69k||no data|
|Member of the Scientific Board||no data||no data||no data|
|Independent Vice Chairman of the Board||2.67yrs||US$199.26k||0.11% |
|Member of Clinical Advisory Board||no data||no data||no data|
|Director||0.083yr||no data||no data|
Experienced Board: GALT's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: GALT insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Galectin Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Galectin Therapeutics, Inc.
- Ticker: GALT
- Exchange: NasdaqCM
- Founded: 2000
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$162.004m
- Shares outstanding: 57.04m
- Website: https://galectintherapeutics.com
Number of Employees
- Galectin Therapeutics, Inc.
- 4960 Peachtree Industrial Boulevard
- Suite 240
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|GALT||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Sep 2002|
|PHPN||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Sep 2002|
Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases. The company’s lead product candidate i ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/21 05:35|
|End of Day Share Price||2020/09/18 00:00|